Alkermes Appoints Anne Whitaker to Board
Analysis based on 7 articles · First reported Sep 16, 2026 · Last updated Sep 16, 2026
The appointment of an independent director to Alkermes' board is a routine governance matter with minimal immediate impact on the company's stock, which traded nearly flat at 46.01 dollars on the Nasdaq. The addition of a seasoned biopharmaceutical executive with commercial and operational expertise may modestly support investor confidence in the company's strategic execution over the longer term.
Alkermes (Nasdaq: ALKS) announced the appointment of Anne C. Whitaker as a new independent director to its Board of Directors. The appointment was announced on Wednesday, September 16, 2026, according to a company press release. Whitaker is a seasoned biopharmaceutical executive and experienced board director with deep commercial and operational expertise and a proven track record of driving growth and transformation across global pharmaceutical and biotechnology organizations. She most recently served as chief executive officer of Ajax Therapeutics, a then clinical-stage biopharmaceutical company. Prior to Aerami, she served as CEO of Novoclem Therapeutics, Inc. and Synta Pharmaceuticals Corporation. Earlier in her career she held senior commercial and executive leadership positions at Bausch Health, Inc., Sanofi S.A. and GlaxoSmithKline. Whitaker currently serves on the boards of publicly traded companies Basilea Pharmaceutica Ltd and ICON PLC, and on the boards of private companies QurAlis LLC, Bespak, Inc., Beaconcure Technologies and Trinity Partners, LLC. She previously served on the boards of Nykode Therapeutics, OraSure Technologies, Inc., Ergomed plc and Faron Pharmaceuticals. She holds a B.S. in chemistry with a minor in business administration from the University of North Alabama. Alkermes CEO Blair Jackson said Anne joins the Board at a defining time for the company, citing strong commercial performance and a differentiated pipeline in neuroscience. Chairman Richard Pops also welcomed her, noting her experience as an executive and CEO across organizations of varying sizes and stages. Alkermes is headquartered in the Republic of Ireland with a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio. On the Nasdaq, Alkermes shares were trading 0.03 percent down at 46.01 dollars following the announcement.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard